Prochlorperazine

立即咨询

Prochlorperazine

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

58-38-8

包装与价格：

包装	价格(元)
10mM (in 1mL DMSO)	电议
100mg	电议
1g	电议

产品介绍

化学性质

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	373.94
Cas No.	58-38-8
Formula	C₂₀H₂₄ClN₃S
Solubility	insoluble in H2O; ≥16.5 mg/mL in DMSO; ≥58.5 mg/mL in EtOH
Chemical Name	2-chloro-10-(3-(4-methylpiperazin-1-yl)propyl)-10H-phenothiazine
Canonical SMILES	CN(CC1)CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(Cl)C=C4
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Prochlorperazine (Compazine, Stemzine, Buccastem, Stemetil, Phenotil) is a dopamine (D2) receptor antagonist that belongs to the phenothiazine class of antipsychotic agents that are used for the antiemetic treatment of nausea and vertigo. It is also a highly potent typical antipsychotic, 10-20x more potent than chlorpromazine. It is also used to treat migraine headaches. Intravenous administration can be used to treat status migrainosus.

试验操作

Cell experiment:[1]
Cell lines	BT474 cells
Reaction Conditions	5 μM prochlorperazine for 2 or 5 d incubation
Applications	In BT474 cells that over-express HER2 and have previously been shown to be tamoxifen resistant, treatment with 5 μM of prochlorperazine in the presence or absence of 4-hydroxytamoxifen significantly inhibited cell proliferation and reduced cyclin E2 mRNA levels. Prochlorperazine has the potential to inhibit proliferation of tamoxifen-resistant breast tumors.
Animal experiment:[2]
Animal models	Beagle dogs, 8 ~ 16 kg
Dosage form	0.34 mg/kg Administered subcutaneously
Applications	Prochlorperazine inhibited emesis induced by apomorphine in dogs, with an ED50 value of 0.34 mg/kg.
Note	The technical data provided above is for reference only.
	References: 1. Huang L, Zhao S, Frasor JM, et al. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoS One, 2011, 6(7): e22274. 2. Niemegeers CJ. Antiemetic specificity of dopamine antagonists. Psychopharmacology (Berl), 1982, 78(3): 210-213.